Olemedia/E+ via Getty Images
- Clinical-stage biopharmaceutical company developing oral therapies — Alumis (ALMS) priced its initial offering of 13.125M shares at $16.00 per share.
- Underwriters have a 30-day over-allotment option to purchase up to an additional 1,968,750 shares.
- Alumis (ALMS)also announced today that it has agreed to sell an additional 2.5Mshares in a concurrent private placement at $16.00 per share to one of its existing investors, AyurMaya Capital Management Fund, LP.
- The shares are expected to begin trading on Nasdaq on June 28, 2024 under the symbol “ALMS.”
- The offering is expected to close on July 1, 2024.
- Gross proceeds from the initial public offering and the concurrent private placement are expected to be $250M.